Introduction Imagine a world where blood shortages no longer threaten patients in need. Every year, hospitals face critical gaps in supply—whether from seasonal drops in donations, unexpected disasters, or the growing demand from cancer treatments and surgeries. In these moments, lives hang in the balance. Now picture a future where blood is not just donated, but manufactured on demand.  Scientists are developing “blood factories”—engineered systems that recreate the environm

Introdution In the past few years, few drugs have generated as much excitement in the world of medicine as tirzepatide, a once-weekly injectable therapy developed by Eli Lilly. Known by its brand names Mounjaro (for diabetes) and Zepbound (for obesity), tirzepatide is being recognized not only as a treatment for blood sugar control and weight loss, but also as a potential revolution in how we manage a wide range of metabolic diseases. This medicine represents a new generation

Introduction In recent years, drugs like tirzepatide and semaglutide, originally developed for diabetes, have captured global attention for their remarkable weight-loss effects. But scientists are now discovering that the benefits of these medicines extend far beyond the bathroom scale. New studies are revealing powerful effects on the heart, liver, and overall metabolism, suggesting that GLP-1 receptor agonists could reshape the way we treat some of the most common chronic d